A study presented at the American Thyroid Association Annual Meeting found that new users of glucagon-like peptide-1 receptor agonists have a low absolute risk of thyroid cancer. Another study at the meeting focused on the prevalence of malignancy in Bethesda III and IV thyroid nodules with negative ThyroSeq results. Additionally, research presented on RET-mutated medullary thyroid cancer showed that the RET inhibitor selpercatinib had robust and durable responses. Efficacy and safety data from clinical trials of the TRK inhibitor larotrectinib for TRK fusion differentiated thyroid cancer were also shared. The studies highlighted the potential benefits of these medications in the management of thyroid cancer.
Source link
Updates on Risk, Diagnosis, and Treatment of Thyroid Cancer
